Rebalancing Diagnosis and Clinical Treatment:
The Contribution of NAPP to Clinical Discourse on Youth Gender Medicine
The management of gender dysphoria and gender incongruence in young people has become one of the most contested areas in contemporary medicine. Amid the evolving landscape of societal attitudes, legal frameworks, and medical practice, the National Association of Practising Psychiatrists (NAPP) has played a pivotal role in rebalancing clinical discourse. Through persistent advocacy, publication of clinical guidelines, and fostering professional dialogue, NAPP has sought to ensure that youth gender medicine is grounded in careful diagnosis, ethical clinical practice, and prioritisation of patient welfare.
Chronology of NAPP’s Contributions
Since 2019, NAPP has been at the forefront of advocating for a rigorous, evidence-based approach to the treatment of young people with gender dysphoria. In October 2019, NAPP wrote to Commonwealth Health Minister Greg Hunt requesting a national inquiry into the treatment practices surrounding gender dysphoria in children. Despite opposition from the Royal Australasian College of Physicians (RACP), which argued such an inquiry might harm vulnerable patients and families, NAPP continued to raise valid concerns about the adequacy and safety of current approaches.
Between 2020 and 2021, NAPP made critical submissions to conversion therapy legislation proposed in Queensland, the Australian Capital Territory, and Victoria. The association cautioned that without precise definitions, conventional psychiatric assessments and treatments risked being misclassified as conversion practices, exposing healthcare providers to potential legal and professional repercussions. NAPP stressed that ethical psychotherapy aimed at exploring underlying causes of distress should not be conflated with coercive practices.
Further, in November 2020, NAPP queried the RACP regarding whether it would reconsider its guidance on gender dysphoria treatment, especially in light of emerging international concerns. Receiving no substantive update, NAPP proceeded to publish the NAPP Guide to Managing Gender Dysphoria/Incongruence in Young People in May 2021, offering clinicians a structured approach based on comprehensive bio-psycho-social assessment and cautious consideration of gender-affirming medical interventions.
In subsequent years, NAPP has remained engaged, revising its guide in December 2023 to incorporate findings from the preliminary report of the UK Cass Review. Its July 2024 webinar with Dr Hilary Cass covered the findings of the final report of the Cass Review. NAPP in April 2026 published a webinar with Prof Rittakerttu Kaltiala on medical reassignment in minors in Finland.
NAPP published an update of its guide to managing gender dysphoria in 2025 integrating advances from international reviews and policy shifts, including the UK government’s 2024 ban on puberty blockers for individuals under 18, the 2025 US Department of Health and Human Services report and more cautious approaches to the treatment of gender dysphoria by Scandinavian countries.
NAPP has also made repeated requests to the Royal Australian and New Zealand College of Psychiatrists (RANZCP) to update guidance in light of these developments. Yet, the RANZCP has remained largely unresponsive, further underlining the need for independent contributions like those of NAPP to shape responsible clinical standards.
Historical Parallels: Homosexuality and Transsexual Identity
The evolving classification of transsexual identity parallels, in some respects, the historical trajectory of homosexuality. Homosexuality progressed from being viewed as evil or immoral, through phases of medicalisation and pathologisation, to eventual acceptance as a normal variation of human sexuality.
Diagnostically, it was removed from the Diagnostic and Statistical Manual (American Psychiatric Association) (DSM) and the International Classification of Diseases (ICD) by the late 20th century.
Transsexual identity has followed a similar path. Initially labelled as a psychiatric disorder—Transsexualism in DSM-III (1980), later as gender identity disorder—trans identities have been progressively de-pathologized. The DSM-5 in 2015 introduced the diagnosis of Gender Dysphoria, focusing on the associated distress rather than the identity itself. The WHO removed gender incongruence from the mental disorders category in ICD-11 (2019).
Dilemma – The Fork in the Road
Homosexual orientation does not require medical intervention. A pressing question now emerges: if transgender identity is to be regarded as a normal variant, does it necessitate medical intervention, particularly when such interventions carry significant risks? Yet transgender advocates demand medical interventions to make trans individuals feel more comfortable with their chosen gender.
Ethical and Legal Considerations
The ethical framework guiding medical decision-making emphasises non-maleficence—”first, do no harm”—and beneficence, whereby doctors act in the best interests of the patient. In the context of youth gender medicine, this requires meticulous assessment to avoid unnecessary or harmful interventions.
Legal precedent in Australia underscores the importance of proportionate and appropriate treatment. Judges Tree and Brennan (Family Court of Australia) have articulated that diagnoses must result from proper assessment, and legitimate treatments must be directed at established pathology or psychiatric disorder and must be both therapeutic and proportionate to their intended purpose.
Applying these principles to gender medicine demands a clear diagnosis, consideration of differential diagnoses, and a careful weighing of anticipated benefits against potential adverse effects.
Clinical Framework: NAPP’s Guide to Managing Gender Dysphoria
The NAPP clinical guide offers a non-ideological, patient-centred approach to youth gender medicine. The young person’s view of their gender identity is genuinely respected, but not affirmed in the initial assessments. The approach outlined in the guide rests on several core principles:
- Comprehensive Bio-Psycho-Social Assessment: A full exploration of the individual’s symptoms and signs, family dynamics, mental health history, and social influences is essential prior to treatment. Co-existing psychiatric conditions and differential diagnoses must be considered. Co-existing psychiatric conditions are usually more than ‘minority stress’.
- First-Line Psychological Interventions: Explorative psychotherapy, psychoeducation, school-home liaison, and family therapy are prioritised. These therapies are exploratory, supporting the young person without promoting any specific gender outcome. NAPP stresses that such practices are distinct from conversion therapy.
- Medical Interventions as Second-Line Options: Puberty blockers and cross-sex hormones are recognised as potentially harmful, with risks to cognitive, reproductive, and psychosexual development. The evidence of benefit is very limited. Therefore, the use of these hormonal interventions is restricted to second-line treatments. International reviews from Finland, Norway, Sweden, and the UK consistently advise caution, limiting or banning such interventions for minors or only allowing them to be used in closely monitored settings or research studies.
- Informed Consent and Capacity: Ensuring that young people and their families fully understand the benefits, limitations, and long-term consequences of medical transition is paramount. The child’s developmental stage and capacity to consent must be rigorously assessed.
International Trends and the Path Forward
Recent developments, including the Cass Review and the closure of the Tavistock Clinic in the UK and similar reviews in the USA and Scandinavian countries, signal a global shift towards more cautious, holistic approaches to gender dysphoria treatment in youth. NAPP has ensured Australian clinicians are informed of these trends, updating its guidelines accordingly.
Conclusion
Through sustained advocacy, scholarly contributions, and clinical leadership, NAPP has made an invaluable contribution to the evolving discourse on youth gender medicine. It has emphasised the importance of ethical practice, comprehensive assessment, and safeguarding the long-term well-being of vulnerable young people. As international evidence mounts in favour of a cautious, balanced approach, NAPP’s efforts to rebalance diagnosis and treatment remain critical to ensuring that youth gender medicine in Australia aligns with best practices, legal principles, and ethical obligations.